EWA
TGTX icon

EverSource Wealth Advisors’s TG Therapeutics TGTX Stock Holding History

EverSource Wealth Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.5K Sell
865
-203
-19% -$8.31K ﹤0.01% 1804
2026
Q1 		$35.5K Buy
1,068
+365
+52% +$10.9K ﹤0.01% 2138
2025
Q4 		$21K Sell
703
-306
-30% -$9.99K ﹤0.01% 2353
2025
Q3 		$36.5K Sell
1,009
-228
-18% -$7.51K ﹤0.01% 1932
2025
Q2 		$44.5K Buy
1,237
+573
+86% +$21.3K ﹤0.01% 1697
2025
Q1 		$26.2K Buy
664
+264
+66% +$8.88K ﹤0.01% 1552
2024
Q4 		$12K Buy
400
+3
+0.8% +$86 ﹤0.01% 1894
2024
Q3 		$9.29K Buy
397
+52
+15% +$1.14K ﹤0.01% 1910
2024
Q2 		$6.82K Buy
345
+342
+11,400% +$5.46K ﹤0.01% 2071
2024
Q1 		$41 Buy
+3
New +$48 ﹤0.01% 2862
2022
Q2 		– Sell
-240
Closed -$2K – 1887
2022
Q1 		$2K Hold
240
– – ﹤0.01% 1584
2021
Q4 		$5K Buy
+240
New +$6.23K ﹤0.01% 1281

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

EverSource Wealth Advisors's TGTX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its TG Therapeutics (TGTX) stake by 19% in Q2 2026, selling an estimated $8.31K and leaving 865 shares worth $47.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

EverSource Wealth Advisors first reported a position in TGTX in Q4 2021 and has held it in 12 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • EverSource Wealth Advisors held 865 shares of TG Therapeutics worth $47.5K as of Q2 2026.
  • EverSource Wealth Advisors sold 203 TG Therapeutics shares in Q2 2026, an estimated $8.31K.
  • TG Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1804 holding.
  • EverSource Wealth Advisors first reported a position in TG Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.